Publications by authors named "Lola Macia-Rivas"

Claim this Profile
D
Dose reduction and toxicity of lenalidomide-dexamethasone in multiple myeloma: A machine-learning prediction model.
Iván Maray, Cristina Álvarez-Asteinza, Clara Luz Fernández-Laguna, Lola Macía-Rivas, Mónica Carbajales-Álvarez

J Oncol Pharm Pract· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin in metastatic breast cancer: Real world data.
Clara Luz Fernández-Laguna, Ivan Maray, Lola Macia-Rivas, Cristina Álvarez-Asteinza, Sergio Fernández-Lastras

Breast Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exacerbation of a thrombotic thrombocytopenic purpura episode linked to different P2Y12 inhibitors in the same patient. Case report.
Lola Macía-Rivas, Iván Maray, Clara L Fernández-Laguna, Cristina Álvarez-Asteinza, Ana Lozano-Blázquez

Farm Hosp· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.
Sena Valcarcel, Javier Gallego, Paula Jimenez-Fonseca, Marc Diez, Eva Martínez de Castro, Lola Macia-Rivas

J Cancer Res Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Data Study of the Efficacy and Toxicity of Nivolumab . Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population.
Lola Macia-Rivas, Clara Luz Fernandez-Laguna, Cristina Alvarez-Asteinza, Ivan Maray, Monica Carbajales-Alvarez

Anticancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis